Sigyn Therapeutics, Inc. Cash Flow Statement
SIGY|5 years of annual SEC 10-K data (FY2014-FY2019)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Sigyn Therapeutics, Inc. used $143,684 in operating cash flow in FY2019.
Based on SEC 10-K filings.
| Item | FY2019 | FY2018 | FY2017 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Net Income | -$3.1M | -$2.6M | -$4.3M | -$2.7M | -$387.5K |
| Depreciation & Amortization | - | $12.7K | $13.7K | - | - |
| Operating Cash Flow | -$143.7K | -$286.1K | -$400.0K | -$83.8K | -$44.4K |
| Capital Expenditures | - | $3.0K | $940 | $2.5K | $3.5K |
| Free Cash Flow | - | -$289.1K | -$400.9K | -$86.3K | -$47.9K |
| FCF Margin | - | -1019.7% | -1043.2% | -295.4% | -111.0% |